References
- Abrams P, Cardozo L, Fall M, Griffiths D, Rosier P, Ulmsten U, et al. The stadardisation of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002;21:167–78.
- Abrams P, Artibani W, Cardozo L, Dmochowski R, van Kerrebroeck P, Sand P. Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009;28:287.
- Murphy AM, Krlin RM, Goldman HB. Treatment of overactive bladder: what is on the horizon? Int Urogynecol J 2013;24:5–13.
- Dowson C, Watkins J, Khan MS, Dasgupta P, Sahai A. Repeated botulinum toxin type A injections for refractory overactive bladder: medium-term outcomes, safety profile, and discontinuation rates. Eur Urol 2012;61:834–9.
- Khera M, Somogyi GT, Salas NA, Kiss S, Boone TB, Smith CP. In vivo effects of botulinum toxin-A on visceral sensory function in chronic spinal cord-injured rats. Urology 2005;66:208–12.
- Krhut J, Zvara P. Intravesical instillation of botulinum toxin-A: an in vivo murine study and pilot clinical trial. Int Urol Nephrol 2011;43:337–43.
- Kuo HC, Liu H-T, Chuang Y-C, Birder LA, Chancellor MB. Pilot study of liposome-encapsulated onabotulinumtoxina for patients with overactive bladder: a single-center study. Eur Urol 2014;65:1117–24.
- Kajbafzadeh A-M, Ahmadi H, Montaser-Kouhsari L, Sharifi-Rad L, Nejat F, Bazargan-Hejazi S. Intravesical electromotive botulinum toxin type A administration-part II: clinical application. Urology 2011;77:439–45.
- Schäfer W, Abrams P, Liao L, Mattiasson A, Pesce F, Spangberg A, et al. International Continence Society. Good urodynamic practices: uroflowmetry, filling cystometry, and pressure-flow studies. Neurourol Urodyn 2002;21:261–74.
- Kovanic PH, Humber MB. The economics of information-mathematical gnostics for data analysis Available from: http://www.math-gnostics.com [last accessed 8 Apr 2015].
- Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D. Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev 2011;7:CD005493.
- Petrou SP, Parker AS, Crook JE, Rogers A, Metz-Kudashick D, Thiel DD. Botulinum A toxin/dimethyl sulfoxide bladder instillations for women with refractory idiopathic detrusor overactivity: a phase 1/2 study. Mayo Clin Proc 2009;84:702–6.
- Soler R, Bruschini H, Truzzi JC, Martins JR, Camara NO, Alves MT, et al. Urinary glycosaminoglycans excretion and the effect of dimethyl sulfoxide in an experimental model of non-bacterial cystitis. Int Braz J Urol 2008;34:503–11.
- Brubaker L, Richter HE, Visco A, Mahajan S, Nygaard I, Braun TM, et al. Refractory idiopathic urge urinary incontinence and botulinum A injection. J Urol 2008;180:217–22.
- Apostolidis A, Fowler CJ. The use of botulinum neurotoxin type A (BoNTA) in urology. J Neural Transm 2008;115:593–605.
- Drake MJ. Mechanisms of action of intravesical botulinum treatment in refractory detrusor overactivity. BJU Int 2008;102(Suppl 1):11–16.
- Kaufman J, Tyagi V, Athony M, Chancellor MB, Tyagi P. State of the art in intravesical therapy for lower urinary tract symptoms. Rev Urol 2010;12:e181–9.
- Fraser MO, Chuang YC, Tyagi P, Yokoyama T, Yoshimura N, Huang L, et al. Intravesical liposome administration – a novel treatment for hyperactive bladder in the rat. Urology 2003;61:656–63.
- J. Knizek, P. Bouchal, B. Vojtesek, R. Nenutil, L. Beranek. Gnostical p-value and gnostical power of test – promising evaluation method of some medicine and biological data. Int J Ecol Econ Stat 2015;6:34–60.